# Tumor Necrosis Factors (TNF)-α Blockade for Psoriatic Arthritis

> **NCT00432406** · PHASE4 · COMPLETED · sponsor: **Chinese University of Hong Kong** · enrollment: 40 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** Infliximab
- **DRUG:** Etanercept

## Key facts

- **NCT ID:** NCT00432406
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2009-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00432406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00432406, "Tumor Necrosis Factors (TNF)-α Blockade for Psoriatic Arthritis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00432406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*